Streetbeat News

Analyst Ratings

BMRN

Wells Fargo analyst Mohit Bansal maintains an Overweight rating on Biomarin Pharmaceutical but lowers the price target from $115 to $90.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 2:10 pm

TBRG

RBC Capital analyst Sean Dodge has reiterated an Outperform rating on TruBridge (NASDAQ:TBRG) and maintained a price target of $14.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 2:09 pm

HIG

Wells Fargo analyst Elyse Greenspan maintains an Overweight rating on Hartford Financial Services Group (NYSE:HIG) and raises the price target from $122 to $134.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 2:09 pm

GOGO

Roth MKM analyst Scott Searle reaffirms a Buy rating on Gogo (NASDAQ:GOGO) with a maintained price target of $15.5.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 2:05 pm

APA

RBC Capital analyst Scott Hanold has reiterated a Sector Perform rating on APA Corporation (NASDAQ:APA) and maintained a price target of $41.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 2:04 pm

FIHL

Goldman Sachs has initiated coverage on Fidelis Insurance Holdings with a Neutral rating and set a price target of $18.5.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 2:03 pm

SMCI

Super Micro Computer (NASDAQ:SMCI) has seen significant options activity, with a majority of trades being bullish. The options trades suggest a focus on a price range between $440 and $700. Analysts have mixed ratings, with some downgrades and price targets around the current trading price.

Portfolio Pulse from Benzinga Insights

September 17, 2024 | 2:01 pm

PFE

Financial giants have shown bearish sentiment on Pfizer (NYSE:PFE) through unusual options activity, with 50% of trades being bearish. Analysts have set a price target of $45, while the current price is $30.0. The next earnings report is expected in 42 days.

Portfolio Pulse from Benzinga Insights

September 17, 2024 | 2:01 pm

BAC

Recent options trading trends indicate a bearish sentiment among large investors towards Bank of America (NYSE:BAC), with 81% of options activity being bearish. This unusual activity suggests potential significant price movements. The stock is currently trading at $39.53, with a recent upgrade from Deutsche Bank to a 'Buy' rating and a target price of $45.

Portfolio Pulse from Benzinga Insights

September 17, 2024 | 2:01 pm

BMRN

RBC Capital analyst Luca Issi maintains a Sector Perform rating on Biomarin Pharmaceutical but lowers the price target from $100 to $85.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 2:01 pm